Biogen Inc (BIIB)
Return on total capital
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 2,165,200 | 2,322,500 | 1,882,200 | 3,018,500 | 3,435,700 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 18,256,800 | 16,716,000 | 14,799,400 | 13,397,900 | 10,896,200 |
| Return on total capital | 11.86% | 13.89% | 12.72% | 22.53% | 31.53% |
December 31, 2025 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $2,165,200K ÷ ($—K + $18,256,800K)
= 11.86%
Peer comparison
Dec 31, 2025
Company name
Symbol
Return on total capital
Biogen Inc
BIIB
11.86%
AbbVie Inc
ABBV
—
Amgen Inc
AMGN
135.75%
Bristol-Myers Squibb Company
BMY
-39.38%
Johnson & Johnson
JNJ
24.40%